Intellectual Property India Publishes Patent Application for 'Pyrazolo[1 5 A]pyridine And Imidazo[1 2 A]pyridine Derivatives As Fgfr3 Inhibitors For The Treatment Of Cancer' Filed by Eli Lilly And Company

MUMBAI, India, March 28 -- Intellectual Property India has published a patent application (202517020234 A) filed by Eli Lilly And Company, Indianapolis, on March 6, for 'pyrazolo[1 5 a]pyridine and imidazo[1 2 a]pyridine derivatives as fgfr3 inhibitors for the treatment of cancer.'

Inventor(s) include Kercher Timothy Scott.

The application for the patent was published on March 28, under issue no. 13/2025.

According to the abstract released by the Intellectual Property India: "The present invention provides compounds of the formula as fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of e.g. cancer systemic sclerosis fibrosis pulmonary fibrosis achondroplasia thanatophoric dysplasia severe achondroplasia with develo...